PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
You are here: Home

Powell departure causes healthcare re-jig at Axa Fram

Deane Donnigan and Antony Milford will oversee Axa Framlington's Biotechnology fund until the group finds a permanent replacement for the departing Gareth Powell. Powell is joining Polar Capital in November, though he will continue to remain

Investment Week Magazine

By Investment Week Magazine
Monday August 13, 2007

Deane Donnigan and Antony Milford will oversee Axa Framlington's Biotechnology fund until the group finds a permanent replacement for the departing Gareth Powell.

Powell is joining Polar Capital in November, though he will continue to remain on the portfolio during his notice period.

He took over the £61m portfolio from Milford in April 2005, and will co-run a long-only healthcare fund with Dan Mahoney at Polar Capital.

Mahoney, from Morgan Stanley, will also join in November.

Meanwhile, Axa Framlington has added Gemma Game to the healthcare team. She will assume lead management responsibilities for the offshore WF Health portfolio.

At BlackRock, Game was a member of the global equities team, with specific responsibility for the healthcare sector.

Milford passed the Healthcare fund to Donnigan in 2005 as he approached retirement, but the group said he still works at least three days a week

Over one year to 30 July, the Biotech fund has produced a bid-to-bid return of 7.9%.


This article is for professional investors only. You will be redirected to the News & Research homepage in seconds. If you are having problems getting to the page, please click here

Videos

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close